Chemomab Therapeutics Ltd.

Chemomab Therapeutics is a clinical-stage biotechnology company headquartered in Tel Aviv-Yafo, Israel, focused on developing therapeutics for fibrotic and inflammatory diseases. The company's pipeline centers on Nebokitug, a humanized monoclonal antibody targeting CCL24, a chemokine involved in disease pathogenesis. Nebokitug has completed Phase 2 clinical trials for primary sclerosing cholangitis (PSC) and is currently enrolled in Phase 2 studies for systemic sclerosis (SSc), a progressive autoimmune condition characterized by fibrosis of skin and internal organs.

The company operates without significant commercial revenue, as its product candidates remain in clinical development stages. Chemomab has not advanced any therapies to commercial markets, meaning revenue streams are currently absent and the business model depends on capital from investors and potential partners rather than product sales.

Founded in 2011, Chemomab maintains its operations in Israel and operates as a publicly listed company on Nasdaq. As a pre-commercial clinical-stage entity, the company's scale remains limited, with financial resources directed toward clinical trial execution, regulatory interactions, and manufacturing of investigational compounds rather than commercial operations or large-scale employment typical of established pharmaceutical firms.